Literature DB >> 15673295

Evidence for stanniocalcin binding activity in mammalian blood and glomerular filtrate.

Kathi James1, Mayaan Seitelbach, Christopher R McCudden, Graham F Wagner.   

Abstract

BACKGROUND: The 50 kD form of the hormone stanniocalcin-1 (STC50) is widely distributed in organs such as kidney, lung, and liver. Kidney collecting duct cells produce STC50 for local targeting to proximal tubule cells to increase phosphate reabsorption. As such the current dogma is that in most organs STC50 is a purely local mediator that is not released into the circulation. However, liver hepatocytes contain high levels of both STC50 and its receptor but little evidence of STC production, suggesting that the hormone may in fact be delivered to hepatocytes systemically. Moreover, previous data suggest that red blood cells may in fact bind STC. In this report, we have sought to identify STC binding activity in mammalian blood.
METHODS: Human, pig, and dog red blood cells were analyzed in STC receptor binding assays. Mouse red blood cells and adult mouse kidney were also analyzed histologically for the presence of STC ligand and receptor.
RESULTS: Saturable, high affinity STC receptors were identified on red blood cells from all species. More intriguingly, STC binding activity was also identified in glomerular filtrate, indicative of a soluble, filterable STC binding protein. This binding protein was subsequently observed being reabsorbed in proximal straight tubules.
CONCLUSION: These findings suggest that our inability to detect STC in mammalian serum is due to its being attached to soluble and tethered forms of a high-affinity binding protein. This could be a means of delivering STC to distant targets as well as a mechanism for removing unwanted hormone from the circulation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15673295     DOI: 10.1111/j.1523-1755.2005.67104.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  7 in total

1.  Stanniocalcin-1 suppresses superoxide generation in macrophages through induction of mitochondrial UCP2.

Authors:  Yanlin Wang; Luping Huang; Maen Abdelrahim; Qingsong Cai; Anh Truong; Roger Bick; Brian Poindexter; David Sheikh-Hamad
Journal:  J Leukoc Biol       Date:  2009-07-14       Impact factor: 4.962

Review 2.  Mammalian stanniocalcin-1 activates mitochondrial antioxidant pathways: new paradigms for regulation of macrophages and endothelium.

Authors:  David Sheikh-Hamad
Journal:  Am J Physiol Renal Physiol       Date:  2009-08-05

3.  Anti-inflammatory and renal protective actions of stanniocalcin-1 in a model of anti-glomerular basement membrane glomerulonephritis.

Authors:  Luping Huang; Gabriela Garcia; Yahuan Lou; Qin Zhou; Luan D Truong; Gabriel DiMattia; Xia Ru Lan; Hui Y Lan; Yanlin Wang; David Sheikh-Hamad
Journal:  Am J Pathol       Date:  2009-02-26       Impact factor: 4.307

4.  Overexpression of stanniocalcin-1 inhibits reactive oxygen species and renal ischemia/reperfusion injury in mice.

Authors:  Luping Huang; Tatiana Belousova; Minyi Chen; Gabriel DiMattia; Dajun Liu; David Sheikh-Hamad
Journal:  Kidney Int       Date:  2012-06-13       Impact factor: 10.612

5.  Characterization of stanniocalcin-1 receptors in the rainbow trout.

Authors:  Timothy D J Richards; Amanda L Fenton; Rahma Syed; Graham F Wagner
Journal:  ISRN Endocrinol       Date:  2012-02-06

6.  Human stanniocalcin-1 suppresses angiotensin II-induced superoxide generation in cardiomyocytes through UCP3-mediated anti-oxidant pathway.

Authors:  Dajun Liu; Luping Huang; Yanlin Wang; Wei Wang; Xander H T Wehrens; Tatiana Belousova; Maen Abdelrahim; Gabriel DiMattia; David Sheikh-Hamad
Journal:  PLoS One       Date:  2012-05-31       Impact factor: 3.240

7.  Stanniocalcin-1 co-localizes with insulin in the pancreatic islets.

Authors:  Deenaz Zaidi; Jeffrey K Turner; Michelle A Durst; Graham F Wagner
Journal:  ISRN Endocrinol       Date:  2012-10-16
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.